Komori
Results briefing materials9267Genky DrugStores Co.,Ltd.Retail

Supplementary Explanatory Materials for the First Quarter of the Fiscal Year Ending June 2027

In the first quarter of the fiscal year ending June 2027, revenue and gross profit exceeded the year-earlier period, while operating profit, ordinary profit and net income fell below the year-earlier period due to higher selling, general and administrative expenses. The full-year forecast calls for revenue of ¥244 billion and operating profit of ¥12 billion, among other figures.

Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
5.3
Year-on-year change in operating income (%)
Wording
Definitive
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFirst quarter of the fiscal year ending June 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥59,503 million+6.2%
Operating profit¥2,763 million-5.3%
Ordinary income¥2,741 million-7.4%
Net income¥1,879 million-7.8%
Gross Profit Margin20.34
Operating profit margin4.6
Selling, general and administrative expenses¥9,341 million
Results for the three months of the current quarter
Net Sales
¥59,503 million
Operating profit
¥2,763 million
Ordinary income
¥2,741 million
Net income
¥1,879 million
Full-year earnings forecast
Net Sales
¥244,000 million
Gross profit
¥49,900 million
Selling, general and administrative expenses
¥37,900 million
Operating profit
¥12,000 million
Ordinary income
¥12,100 million
Net income
¥8,200 million
What the company explained in this material
Key KPIsA metric the company considers important as a management benchmark.
  • Same-store sales (SSS)-0.1 %
  • Stores at Period End541 Location
  • Revenue / tsubo¥1,354 thousand / tsubo・year
  • Operating profit / tsubo¥67 thousand / tsubo・year
Number of stores and locations
Number of Stores at Period-End541 Location
Stores opened during the period9 Location
Store closures during the period2 Location
Capital expenditures
¥20,278 million CFI ≒ CAPEX
Annual Dividend
Annual dividend per share¥13
Payout ratio
5 %
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFirst quarter of the fiscal year ending June 2027
Net Sales¥59,503 million (YoY +6.2%)
Operating profit¥2,763 million (YoY -5.3%)
Ordinary income¥2,741 million (YoY -7.4%)
Net income¥1,879 million (YoY -7.8%)
Gross Profit Margin20.34
Operating profit margin4.6
Selling, general and administrative expenses¥9,341 million
Results for the three months of the current quarterNet Sales ¥59,503 million / Operating profit ¥2,763 million / Ordinary income ¥2,741 million / Net income ¥1,879 million
Full-year earnings forecastNet Sales ¥244,000 million / Gross profit ¥49,900 million / Selling, general and administrative expenses ¥37,900 million / Operating profit ¥12,000 million / Ordinary income ¥12,100 million / Net income ¥8,200 million
Key KPIsIndicator name Same-store sales (SSS) / Value -0.1 % / Year on year against the same period last year Not disclosed, Indicator name Stores at Period End / Value 541 Location / Year on year against the same period last year Not disclosed, Indicator name Revenue / tsubo / Value ¥1,354 thousand / tsubo・year / Year on year against the same period last year Not disclosed, Indicator name Operating profit / tsubo / Value ¥67 thousand / tsubo・year / Year on year against the same period last year Not disclosed
Number of stores and locationsNumber of Stores at Period-End 541 Location / Stores opened during the period 9 Location / Store closures during the period 2 Location
Annual DividendAnnual dividend per share ¥13
Payout ratio5 %
Capital expenditures¥20,278 million (CFI ≒ CAPEX)
Items this document does not state (15)
Progress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No specific written explanation has been provided for the decline in operating profit. Selling, general and administrative expenses increased 10.8% year on year. The full-year net income forecast also incorporates the impact of being ineligible for tax credits under the tax incentive for promoting wage increases, as well as the additional impact of the defence special corporate tax.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Explanatory Materials for the First Quarter of the Fiscal Year Ending June 2027 | Genky DrugStores Co.,Ltd. (9267) timely disclosure | Komori